Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen (Q39600656)

13 September 2017

Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen (English)

1 reference

13 September 2017

T Tauchi

1

1 reference

13 September 2017

S Okabe

2

1 reference

13 September 2017

E Ashihara

3

1 reference

13 September 2017

S Kimura

4

1 reference

13 September 2017

T Maekawa

5

1 reference

13 September 2017

K Ohyashiki

6

1 reference

13 September 2017

language of work or name

English

0 references

publication date

31 January 2011

1 reference

13 September 2017

1 reference

13 September 2017

30

1 reference

13 September 2017

24

1 reference

13 September 2017

2789-2797

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2011.3

13 September 2017

0 references

cites work

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: role of p38 mitogen-activated protein kinase and NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.3

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.3

1 reference

Dimensions Publication ID

13 September 2017

1003205620

0 references

Fatcat ID

release_n3qjxtcr35axffebfsnuew3lbe

0 references

1 reference